OncoMatch/Clinical Trials/NCT07112222
A Study of LM-350 in Subjects With Advanced Solid Tumours
Is NCT07112222 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies LM-350 for for malignant tumors.
Treatment: LM-350 for — For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
Patients with advanced solid tumors...who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.
Cannot have received: same targeting
Subjects who have received treatment with the same targeting.
Cannot have received: topoisomerase inhibitor
Exception: history of ≥ Grade 3 late diarrhea during or after previous treatment
History of ≥ Grade 3 late diarrhea during or after previous treatment with a topoisomerase inhibitor.
Cannot have received: anti-tumor treatments within the specified time periods
Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.
Lab requirements
Blood counts
adequate organ and bone marrow function as defined by protocol
Kidney function
adequate organ and bone marrow function as defined by protocol
Liver function
adequate organ and bone marrow function as defined by protocol
Adequate organ and bone marrow function as defined by protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify